What You Should Know About Adverse Events of Bispecific Antibodies: Expert Consensus on Management in Multiple Myeloma
Start Date
November 5th, 2024
Expiration Date
November 5th, 2025
Media Type
Internet
Completion Time
30 minutes
Specialty
Case Management, Critical Care, Hematology-Oncology, Hospitalist
Topic(s)
Pharmacology, Multiple Myeloma, Oncology
This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.
This program has been supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Credit Available
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
The primary target audience for this activity are Academic and community-based physicians and team members, including hematologists, hematologic oncologists, medical oncologists, oncology nurses, NPs, PAs, and hematology-oncology pharmacists.
Statement of Need/Program Overview
Bispecific antibodies are relatively new agents in the treatment of multiple myeloma (MM). Because of this, many oncology clinicians are unfamiliar with their mechanism of action and the adverse events associated with these agents, as well as having limited guidance on appropriate management with these options. Two expert key opinion leaders in MM care will share guidance for clinicians in the community on how to manage transitions of care from academic centers, as well as explore considerations for the inpatient and outpatient setting. The education will also provide insights and best-practice recommendations on appropriate adverse-event management while utilizing bispecific antibodies to manage people with relapsed/refractory MM.
Learning Objectives
After completing this activity, the participant should be better able to:
- Apply expert consensus recommendations for adverse-event management related to bispecific antibodies for the treatment of MM
- Discuss implications for management at the site of treatment vs follow-up management at a community center
- Assess operationalization of team-based adverse-event protocols for patients on bispecific antibodies
Faculty
Krina Patel, MD
Associate Professor
Multiple Myeloma Section Chief
Department of Lymphoma Myeloma
Division of Cancer Medicine
University of Texas, MD Anderson Cancer Center
Joshua Richter, MD, FACP
Associate Professor of Medicine
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Direct of Myeloma, Blavatnik Family
Chelsea Medical Center at Mount Sinai
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation
PACE designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
- Krina Patel, MD
- Consultant, Advisor, Speaker: Bristol Myers Squibb, Oricle, Kite, Celgene, Johnson & Johnson, Legend Biotech, Pfizer, Merck, Oncopeptides, AbbVie, PrecisionBio, AstraZeneca, Sanofi, Novartis
- Researcher: Bristol Myers Squibb, Celgene, Johnson & Johnson, AbbVie, Takeda, Poseida
- Joshua Richter, MD, FACP
- Consultant, Advisor, Speaker: Janssen, Bristol Myer Squibb, Sanofi, Adaptive Biotechnologies, Pfizer, Karyopharm, Takeda, Genentech, Abbvie, Regeneron, Forus, Menarini
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support:
For additional information about the accreditation of this activity, please visit https://partnersed.com
Technical Support:
For any technical issues or issues with your CME Certificate, please contact MedLive at 877-394-1306 or at [email protected]
PlatformQ Health Privacy Policy:
By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at [email protected]
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting [email protected] with the subject line “Data Request”
You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/